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Background: Overweight or obesity contributes to the development of type 2 diabetes mellitus (T2DM) and increases
cardiovascular risk. Exenatide, a glucagon-like peptide-1 receptor agonist, significantly reduces glycated hemoglobin
(A1C) and body weight and improves cardiovascular risk markers in patients with T2DM. As weight loss alone has been
shown to reduce A1C and cardiovascular risk markers, this analysis explored whether weight loss contributed
importantly to clinical responses to exenatide once weekly.
Methods: A pooled analysis from eight studies of exenatide once weekly was conducted. Patients were distributed
into quartiles from greatest weight loss (Quartile 1) to least loss or gain (Quartile 4). Parameters evaluated for each
quartile included A1C, fasting plasma glucose (FPG), blood pressure (BP), heart rate, high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides, and the liver enzymes alanine
aminotransferase (ALT) and aspartate aminotransferase (AST).
Results: The median changes from baseline in body weight in Quartiles 1–4 were −6.0, –3.0, −1.0, and +1.0 kg,
respectively. All quartiles had reductions in A1C (median changes −1.6, −1.4, −1.1, and −1.2%, respectively) and
FPG (−41, −40, −31, and −25 mg/dL, respectively), with the greatest decreases in Quartiles 1 and 2. Most cardiovascular
risk markers (except diastolic BP) and liver enzymes improved in Quartiles 1 through 3 and were relatively unchanged
in Quartile 4. Higher rates of gastrointestinal adverse events and hypoglycemia were observed in Quartile 1 compared
with Quartiles 2 through 4.
Conclusions: Exenatide once weekly improved glycemic parameters independent of weight change, although the
magnitude of improvement increased with increasing weight loss. The greatest trend of improvement in glycemic
parameters, cardiovascular risk factors including systolic BP, LDL-C, total cholesterol, and triglycerides, and in liver
enzymes, was seen in the patient quartiles with the greatest reductions in body weight.
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The increased incidence of new diabetes is significantly
associated with the increased incidence and prevalence
of overweight and obesity [1-3] and reduction of excess
body weight may be helpful for patients with diabetes.
Treatment guidelines recommend weight loss and greater* Correspondence: lblonde@ochsner.org
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gression from prediabetes to overt type 2 diabetes mellitus
(T2DM) [4,5]. It is also a corner stone of treatment for
those with type 2 diabetes and a complement to glucose-
lowering pharmacotherapy [4-6]. Weight reduction alone
may improve glycemic control and have beneficial effects
on cardiovascular (CV) risk factors. In the Look AHEAD
(Action for Health in Diabetes) study, patients randomized
to intensive lifestyle interventions lost 8.6% of their body
weight from baseline after 1 year, and this weight. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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hemoglobin (A1C) (−0.6%) and fasting plasma glucose
(FPG) (−21.5 mg/dL) [7]. Multiple CV risk factors were
also ameliorated, though the 5% decrease in the primary
end point, a composite of cardiovascular death, nonfatal
myocardial infarction or stroke, or hospitalization for
angina, was not statistically significant (P = 0.51) [7,8].
Exenatide, a glucagon-like peptide-1 receptor agonist
(GLP-1RA), which is available in twice daily or once weekly
formulations, has been shown to improve glycemic control
and reduce excess body weight in patients with T2DM.
Studies of exenatide once weekly demonstrated mean
reductions in A1C ranging from −1.3% to −1.9% and
mean weight reduction ranging from −2.0 kg to −3.7 kg
[9-16]. Exenatide once weekly has also been associated
with the significant improvement of a variety of CV
risk markers, including blood pressure, lipids, and an-
thropomorphic measurements [9,11-16].
The contribution of weight loss to the clinical effects
observed with exenatide once weekly is not known. An
analysis was conducted to determine if improvements in
glycemic parameters and CV risk markers might result
from or occur independently of body weight loss.
Materials and methods
Pooled data were analyzed using the intent-to-treat (ITT)
patient population receiving exenatide once weekly, with
or without oral glucose-lowering medications, from eight
randomized, controlled 24- to 30-week trials (Table 1)
[9-16]. Patients enrolled in the studies were at least
16 years of age with T2DM, an A1C of 7.1 to 11.0%,
stable body weight (3–6 months prior to enrollment), and
body mass index (BMI) of 23 to 45 kg/m2. Quartiles wereTable 1 Characteristics of exenatide once weekly studies
Author N Study duration
(weeks)
Baseline
Drucker et al. 2008 [14] 148 30 8.3
(DURATION-1)
Bergenstal et al. 2010 [9] 160 26 8.6
(DURATION-2)
Diamant et al. 2010 [13] 233 26 8.3
(DURATION-3)
Russell-Jones et al. 2012 [16] 248 26 8.5
(DURATION-4)
Blevins et al. 2011 [10] 129 24 8.5
(DURATION-5)
Buse et al. 2013 [11] 461 26 8.5
(DURATION-6)
Davies et al. 2013 [12] 111 26 8.4
Ji et al. 2013 [15] 340 26 8.7
A1C: glycated hemoglobin; aAll mean or least-squares mean values; bAt study end pcreated by dividing the total patient population into four
approximately equal subgroups based on body weight
change from baseline: Quartile 1 consisted of the 25% of
subjects with the greatest weight loss at the end of the
controlled period; Quartile 4 consisted of the 25% of sub-
jects with the smallest weight reduction (or weight gain).
Laboratory data available for each study included A1C,
FPG, high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), total cholesterol,
triglycerides, alanine aminotransferase (ALT), and aspar-
tate aminotransferase (AST). A single laboratory was used
for the measurements in each study, but the same labora-
tory was not used for all studies. Vital signs available for
each study included systolic blood pressure (SBP), diastolic
blood pressure (DBP), and heart rate (HR). Laboratory
data and vital signs were collected at baseline and at
regular intervals through study end point.
In the analysis, efficacy data included glycemic param-
eters (A1C and FPG) and CV risk markers (SBP, DBP,
HR, HDL-C, LDL-C, total cholesterol, and triglycerides),
and safety data included liver enzymes (ALT and AST),
the number of adverse events, and the incidence of severe
and non-severe hypoglycemia. Severe hypoglycemia was
defined as symptoms resulting in loss of consciousness or
seizure that showed prompt recovery after administration
of glucose, or documented blood glucose <54 mg/dL
that required third-party assistance because of severe
impairment in consciousness or behavior. Non-severe
hypoglycemia was defined as signs or symptoms of
hypoglycemia accompanied by fingerstick blood glucose
<54 mg/dL. Baseline demographics and adverse events
were summarized by descriptive statistics by weight quar-
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baseline to end point with median changes by quartile and
mean changes with 95% confidence intervals (CIs) calcu-
lated by quartile and for the ITT population. To examine
the linear dependence of the change in body weight onTable 2 Patient demographics and clinical characteristics
Characteristic Quartile 1





Male, n (%) 223 (49.0) 249
Age (y), mean (SD) 56 (9) 57 (
Known diabetes duration (y), mean (SD) 7 (6) 7 (6
Race, n (%)
White 320 (70.3) 284
Black 8 (1.8) 9 (2
Hispanic 32 (7.0) 36 (
Asian 89 (19.6) 123
Other 6 (1.3) 6 (2
Glucose-lowering background treatment, n (%)b
Diet and exercise only 72 (15.8) 52 (
Insulin 3 (0.7) 1 (0
Metformin 373 (82.0) 388
Thiazolidinedione 22 (4.8) 19 (
Sulfonylurea 172 (37.8) 212
A1C (%), mean (SD) 8.3 (1.0) 8.4 (
FPG (mg/dL), mean (SD) 167.0 (44.2) 170.
Body weight (kg), mean (SD) 93.7 (21.0) 85.3
BMI (kg/m2)
Mean (SD) 33.3 (5.7) 30.8
Category
<30 143 (31.4) 222
≥30 310 (68.1) 235
Missing 2 (0.4) 1 (0
SBP (mm Hg), mean (SD) 130.5 (14.8) 131.
DBP (mm Hg), mean (SD) 78.6 (8.8) 78.7
HR (beats per minute), mean (SD) 74.1 (9.4) 74.8
ALT (U/L), mean (SD)c 32.8 (19.2) 32.2
AST (U/L), mean (SD)d 26.9 (12.8) 25.9
Lipids (mg/dL), mean (SD)
Total cholesterol 176.7 (42.3) 178.
LDL-C 98.7 (34.7) 99.5
HDL-C 43.9 (11.85) 44.2
Triglycerides 183.0 (147.1) 184.
A1C: glycated hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotran
plasma glucose; HDL-C: high-density lipoprotein cholesterol; HR: heart rate; LDL-C: l
deviation; aRange of weight change per quartile; bValues are presented as incidence
indicated; cALT normal values: 10 to 40 U/L; dAST normal values: 10 to 34 U/L.the change in A1C, Pearson correlation coefficients were
calculated by quartile and for the ITT population.
Studies included in the analysis were conducted in ac-
cordance with the Declaration of Helsinki. Study proto-
cols were approved by an institutional review board atrtile 2
1 to −2.0 kg)a
458)
Quartile 3
(−2.0 to −0.1 kg)a
(n = 450)
Quartile 4




(54.4) 257 (57.1) 283 (62.2) 1015 (55.5)
10) 55 (10) 54 (11) 55 (10)
) 7 (6) 6 (5) 7 (6)
(62.0) 245 (54.4) 251 (55.2) 1104 (60.3)
.0) 14 (3.1) 16 (3.5) 48 (2.6)
7.9) 34 (7.6) 42 (9.2) 147 (8.0)
(26.9) 153 (34.0) 142 (31.2) 511 (27.9)
.6) 4 (0.9) 4 (0.9) 20 (1.1)
11.4) 72 (16.0) 90 (19.8) 291 (15.9)
.2) 3 (0.7) 1 (0.2) 8 (0.4)
(84.7) 355 (78.9) 330 (72.5) 1453 (79.4)
4.1) 27 (6.0) 32 (7.0) 100 (5.5)
(46.3) 207 (46.0) 201 (44.2) 798 (43.6)
1.0) 8.5 (1.1) 8.7 (1.1) 8.5 (1.1)
9 (45.7) 170.9 (46.2) 175.6 (50.8) 171.2 (46.9)
(18.9) 85.3 (19.1) 87.7 (21.3) 88.0 (20.4)
(5.6) 30.8 (5.3) 30.9 (5.6) 31.5 (5.6)
(48.5) 216 (48.0) 217 (47.7) 801 (43.8)
(51.3) 228 (50.7) 236 (51.9) 1018 (55.6)
.2) 6 (1.3) 2 (0.4) 11 (0.6)
6 (15.2) 131.3 (14.3) 129.9 (14.2) 130.8 (14.7)
(9.2) 80.1 (8.6) 79.1 (9.2) 79.1 (8.9)
(9.1) 75.2 (9.6) 74.9 (9.8) 74.7 (9.5)
(19.1) 33.4 (19.6) 34.2 (21.8) 33.1 (19.9)
(12.7) 26.2 (11.2) 26.4 (12.2) 26.3 (12.2)
3 (43.4) 177.2 (41.7) 184.9 (43.2) 179.3 (42.7)
(37.2) 99.2 (34.5) 104.3 (37.9) 100.4 (36.0)
(11.54) 44.9 (12.32) 45.2 (12.52) 44.5 (12.1)
8 (147.0) 175.5 (121.6) 190.5 (141.4) 183.5 (139.6)
sferase; BMI: body mass index; DBP: diastolic blood pressure; FPG: fasting
ow-density lipoprotein cholesterol; SBP: systolic blood pressure; SD: standard
of use, with or without other glucose-lowering therapies, unless otherwise
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informed consent.
Results
The analysis included pooled data from 1830 patients.
Patient demographic and clinical characteristics by quartile
and for the population as a whole are shown in Table 2. Pa-
tients had at baseline a mean age of 55 years, mean BMI
31.5 kg/m2, mean A1C 8.5%, mean BP 130.8/79.1 mm Hg,
and mean LDL-C 100.4 mg/dL. At baseline, the majority of
patients were taking metformin (79.4%), less than half were
taking a sulfonylurea (43.6%), and less than one-fifth were
treated only with lifestyle interventions of medical nutri-
tion therapy and physical activity (15.9%). Baseline charac-
teristics in different quartiles of weight loss were mostly
evenly distributed with respect to age and known diabetes
duration. Mean A1C and FPG baseline values were the
lowest in Quartile 1 and trended upward across body
weight change quartiles. Body weight was reduced in
three of four quartiles. The median change from base-
line in body weight was −6.0 kg in Quartile 1, −3.0 kg
in Quartile 2, −1.0 kg in Quartile 3, and +1.0 kg in
Quartile 4 (Figure 1).
Some inter-quartile differences in patient baseline char-
acteristics were noted (Table 2). The proportion of male
patients was greatest in Quartile 4, with the smallest pro-
portion in Quartile 1. Metformin use was the highest in
Quartile 2 and the lowest in Quartile 4, and sulfonylurea
use was the highest in Quartile 2 and the lowest in
Quartile 1. Baseline body weight was the highest in
Quartile 1 compared with the remaining quartiles, which
were mostly similar, and the highest baseline lipid values
occurred in Quartile 4.
Clinically relevant A1C and FPG reductions were ob-
served across all body weight change quartiles. TheFigure 1 Distribution of median change in body weight, by
end-point body weight change quartiles. The central line represents
the median (also labelled above the plot), the box encloses the 25th
to 75th percentiles of the distribution, and the outer bars are drawn
to the 10th and 90th percentiles.median change from baseline in A1C was −1.6% in
Quartile 1, −1.4% in Quartile 2, −1.1% in Quartile 3, and
−1.2% in Quartile 4 (Figure 2A). The mean (standard
error) changes in A1C with 95% confidence intervals by
Quartile are presented in Table 3.
The mean changes in A1C for all quartiles are presented
in Table 3. A higher proportion of patients achieved A1C
targets in the quartiles with the greatest weight loss. In
Quartiles 1, 2, 3, and 4, an A1C of <7% was achieved by
76.0%, 63.3%, 46.0%, and 37.1% of patients, respectively,
and an A1C of ≤6.5% was achieved by 57.6%, 42.1%,
26.9%, and 19.6% of patients, respectively. The scatter-plot
along with the regression line exhibits the linear depend-
ence between change in body weight and change in A1C,
which was found to be weak overall (Figure 3). The
change in median FPG followed a similar pattern across
body weight loss quartiles as A1C values: −41 mg/dL in
Quartile 1, −40 mg/dL in Quartile 2, −31 mg/dL in
Quartile 3, and −25 mg/dL in Quartile 4 (Figure 2B).
The greatest improvements in CV risk markers were
observed in Quartile 1, where 50% to 75% of patients
showed decreases from baseline in median SBP, LDL-C,
total cholesterol, and triglycerides by study end point;
HDL-C was slightly increased (Figures 4A–F). In
Quartiles 2 and 3, improvements in CV risk markers
were smaller compared with those in Quartile 1. In
Quartile 4, all CV risk markers were mostly unchanged
from baseline except for LDL-C and total cholesterol. The
greatest increase in HR occurred in Quartile 1 (mean 3.4
beats per minute) and varied across Quartiles 2 through 4
(mean 2.2–2.9 beats per minute).
Modest decreases in ALT and AST were observed in
the quartile with the greatest body weight reduction
(Figures 5A and B). Improvements were minimal or
absent across the remaining quartiles. ALT and AST
values were within normal limits at study end point.
Treatment-emergent adverse events reported by at least
5% of patients treated with exenatide once weekly in
the overall population are shown in Table 4. The most
commonly reported adverse events were hypoglycemia
(17.3% of patients), nausea (16.7%), and diarrhea (11.3%).
Hypoglycemic events were more frequently reported
among patients receiving background sulfonylurea ther-
apy compared with those patients who did not receive
sulfonylurea treatment (28.8% vs 8.3%).
The incidence of treatment-emergent adverse events
was higher overall in the quartile with the greatest weight
loss from baseline. The proportion of patients with
hypoglycemia decreased across body weight loss quar-
tiles from 20.9% in Quartile 1 to 19.0% in Quartile 2,
16.7% in Quartile 3, and 13.0% in Quartile 4. In each
quartile, hypoglycemia rates were higher in sulfonylurea
users compared with non-users (Quartile 1: 37.2% vs
11.0%; Quartile 2: 34.0% vs 6.1%; Quartile 3: 25.1% vs
Figure 2 Median changes in A1C and FPG, by end-point body weight change quartiles. (A) A1C. (B) FPG. A1C, hemoglobin A1C; FPG,
fasting plasma glucose. The central line represents the median (also labelled above the plot), the box encloses the 25th to 75th percentiles of the
distribution, and the outer bars are drawn to the 10th and 90th percentiles.
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verse events showed a similar trend with higher rates in
Quartiles 1 and 2. Nausea was reported in 22.0% of pa-
tients in Quartile 1, 17.9% in Quartile 2, 13.8% in Quar-
tile 3, and 13.2% in Quartile 4.Table 3 Mean changes in parameters from baseline to end po
Parameter, mean (SE)
[95% CI]
Quartile 1 Quartile 2
(n = 455) (n = 458)
Weight (kg) −7.0 (0.15) −3.0 (0.03)
[−7.3, −6.7] [−3.0, −2.9]
A1C (%) −1.7 (0.05) −1.4 (0.05)
[−1.8, −1.6] [−1.5, −1.3]
FPG (mg/dL) −43.5 (2.30) −38.3 (2.29)
[−48.0, −39.0] [−42.8, −33.8]
SBP (mm Hg) −5.8 (0.71) −3.7 (0.68)
[−7.2, −4.4] [−5.1, −2.4]
DBP (mm Hg) −1.1 (0.43) −1.4 (0.41)
[−1.9, −0.2] [−2.2, −0.6]
HR (beats per minute) 3.4 (0.48) 2.8 (0.44)
[2.5, 4.4] [1.9, 3.7]
HDL-C (mg/dL) 0.9 (0.31) 0.7 (0.30)
[0.3, 1.5] [0.2, 1.3]
LDL-C (mg/dL) −6.1 (1.23) −5.9 (1.15)
[−8.5, −3.6] [−8.2, −3.7]
Total cholesterol (mg/dL) −9.3 (1.53) −8.2 (1.39)
[−12.3, −6.3] [−11.0, −5.5]
Triglycerides (mg/dL) −26.1 (7.40) −19.7 (5.70)
[−40.7, −11.6] [−30.9, −8.5]
ALT (U/L) −8.2 (0.67) −3.3 (0.78)
[−9.6, −6.9] [−4.8, −1.8]
AST (U/L) −5.9 (0.77) −3.3 (0.82)
[−7.5, −4.4] [−4.9, −1.7]
A1C: glycated hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotran
plasma glucose; HDL-C: high-density lipoprotein cholesterol; HR: heart rate; LDL-C: lDiscussion
In this analysis of pooled data, the majority of patients
with T2DM treated with exenatide once weekly showed
body weight loss. However, clinically meaningful glycemic
improvement was seen regardless of change in bodyint
Quartile 3 Quartile 4 All Patients
(n = 450) (n = 455) (N = 1830)
−1.0 (0.03) 1.5 (0.09) −2.4 (0.09)
[−1.1, −1.0] [1.4, 1.7] [−2.5, −2.2]
−1.2 (0.06) −1.3 (0.05) −1.4 (0.03)
[−1.3, −1.1] [−1.4, −1.2] [−1.5, −1.3]
−31.7 (2.13) −29.1 (2.50) −35.7 (1.16)
[−35.9, −27.6] [−34.1, −24.2] [−38.0, −33.5]
−3.1 (0.60) −0.5 (0.60) −3.3 (0.33)
[−4.2, −1.9] [−1.7, 0.7] [−3.9, −2.6]
−1.1 (0.40) 0.3 (0.44) −0.8 (0.21)
[−1.9, −0.3] [−0.5, 1.2] [−1.2, −0.4]
2.2 (0.46) 2.9 (0.48) 2.8 (0.23)
[1.3, 3.1] [1.9, 3.8] [2.4, 3.3]
0.0 (0.33) −0.2 (0.34) 0.4 (0.16)
[−0.6, 0.7] [−0.9, 0.5] [0.1, 0.7]
−1.3 (1.25) −1.0 (1.36) −3.6 (0.63)
[−3.8, 1.1] [−3.7, 1.7] [−4.8, −2.4]
−2.5 (1.47) −1.5 (1.62) −5.4 (0.76)
[−5.4, 0.4] [−4.7, 1.7] [−6.9, −3.9]
−6.2 (4.64) 0.5 (5.99) −13.0 (3.02)
[−15.3, 2.9] [−11.3, 12.3] [−19.0, −7.1]
−2.9 (0.76) 1.2 (1.44) −3.3 (0.48)
[−4.4, −1.4] [−1.7, 4.0] [−4.3, −2.4]
−1.2 (0.83) −1.5 (1.06) −3.2 (0.44)
[−2.8, 0.5] [−3.6, 0.6] [−4.1, −2.3]
sferase; CI: confidence interval; DBP: diastolic blood pressure; FPG: fasting
ow-density lipoprotein cholesterol; SBP: systolic blood pressure.
Figure 3 Pearson linear correlation of change in body weight and change in A1C. The solid black line represents the regression. Dotted
lines represent the maximum body weight change in Quartiles 1 through 3. The r-value for all patients was 0.1579, and r-values for Quartiles 1
through 4 were 0.1847, 0.0267, 0.0485, and −0.0542, respectively. A1C, hemoglobin A1C; Q, quartile.
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across all quartiles, including Quartile 4, which had
modest weight gain, although the correlation between
change in weight and change in A1C was found to be
weak overall. This suggests that both A1C and weight
reduction are indications of a positive response to exe-
natide; those patients with the most positive response
have the greatest reductions in both A1C and weight.
The findings of the present analysis are similar to those
of two previous analyses of exenatide twice daily and at
least one analysis of liraglutide, in which A1C reductions
were observed in all body weight change quartiles and the
magnitude of glycemic improvement generally was larger
in those with greater body weight loss [17-19].
Effects beyond glycemic control
Beyond the control of glucose and improvement of weight,
multiple mechanistic studies in animals suggest that
GLP-1 receptor agonism has additional positive effects
including increased pancreatic beta cell mass [20], aortic
vasodilation [21], cardiac protection against ischemia or
reperfusion injury [22], and protection against hepatic
lipid accumulation [23]. While the relevance of these
findings in humans is unknown, improvements in CV
risk markers (excluding DBP) and liver enzymes from
baseline were observed with exenatide once weekly in
the majority of body weight loss quartiles and with the
greatest improvement in the quartile with the greatestreduction of body weight. The magnitude of improvement
for these parameters increased with greater weight loss,
similar to what was observed in previous analyses of exe-
natide twice daily by weight loss quartile [17,18,24]. The
lack of reductions in DBP across quartiles is in contrast to
results observed with one previous analysis of exenatide
twice daily that demonstrated a positive relationship be-
tween weight loss and improvement in DBP [17]. The
present analysis is the first to report changes in HR across
body weight loss quartiles with GLP-1RA therapy. The
magnitude of HR increase was small overall and the in-
crease became smaller with less body weight loss.
Whether the observed improvements in CV risk markers
with exenatide once weekly translate to improvements
in CV-related end points or outcomes is not presently
known. At least one outcomes study looking into CV
end points with exenatide once weekly is currently in
progress (Exenatide Study of Cardiovascular Event Lowering
Trial [EXSCEL], NCT01144338) and is estimated to be
completed in March 2018.
A trend of increased incidence of both gastrointestinal
adverse events and hypoglycemia was observed with in-
creased weight loss, the reason for which is not defini-
tively known. Approximately 80% of patients in Quartile
1 lost weight without any nausea events. However, more
patients in the highest quartile of body weight loss expe-
rienced nausea than in the lowest quartile, suggesting
that nausea may be associated with greater weight loss
Figure 4 Median changes in blood pressure and lipids, by end-point body weight change quartiles. (A) SBP. (B) DBP. (C) HDL-C. (D) LDL-C.
(E) Total cholesterol. (F) Triglycerides. DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; SBP, systolic blood pressure. The central line represents the median (also labelled above the plot), the box encloses the 25th to
75th percentiles of the distribution, and the outer bars are drawn to the 10th and 90th percentiles.
Figure 5 Median changes in ALT and AST, by end-point body weight change quartiles. (A) ALT. (B) AST. ALT, alanine aminotransferase;
AST, aspartate aminotransferase. The central line represents the median (also labelled above the plot), the box encloses the 25th to 75th percentiles of
the distribution, and the outer bars are drawn to the 10th and 90th percentiles.
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Table 4 Treatment-emergent adverse events reported by
at least 5% of patients treated with exenatide once
weekly





Injection site nodule 141 (7.7)
Vomiting 128 (7.0)
Constipation 109 (6.0)
Injection site pruritus 101 (5.5)
All* Severe† Non-severe‡
Hypoglycemia 317 (17.3)
Background sulfonylurea use 230 (28.8) 0 (0.0) 104 (13.0)
No background sulfonylurea use 86 (8.3) 1 (0.1) 23 (2.2)
*All hypoglycemia: includes severe, non-severe, and symptoms of hypoglycemia
(defined as any episode of hypoglycemia that does not meet severe or non-severe
event criteria); †Severe hypoglycemia: symptoms resulting in loss of consciousness
or seizure that showed prompt recovery after administration of glucose, or
documented blood glucose <54 mg/dL that required third-party assistance
because of severe impairment in consciousness or behavior; ‡Non-severe
hypoglycemia: signs or symptoms of hypoglycemia accompanied by fingerstick
blood glucose <54 mg/dL.
Blonde et al. Cardiovascular Diabetology  (2015) 14:12 Page 8 of 10or responsiveness to therapy [25]. At baseline, the ma-
jority of patients were taking metformin; thus, it is pos-
sible that metformin use may have contributed to the
increased incidence of GI adverse events. However, such
an effect would be expected to impact all quartiles since
baseline metformin use was high across each quartile.
The increased incidence of hypoglycemia in patients with
increased weight loss might also signal a greater respon-
siveness (e.g., more insulin secretion) to exenatide therapy.
Sulfonylureas have been shown to uncouple the glucose
dependence of GLP-1 receptor activation and increase
overall insulin secretion in the rat pancreas when co-
infused with GLP-1 [26]. Rates of hypoglycemia were
higher overall with concomitant sulfonylurea use com-
pared with non-use and followed the same overall trend
of increased hypoglycemia with increased weight loss. It
should be noted, that the reported rates of hypoglycemia
included patients with reported hypoglycemia symptoms
not confirmed by fingerstick glucose in addition to the
more strictly defined severe and non-severe hypoglycemia;
thus hypoglycemia rates may have been higher overall
than expected.
Limitations
Several confounding factors may have impacted the
observed results. There were a few imbalances in the
baseline demographics across quartiles that could have
influenced these findings. For example, glycemic re-
sponse and use of background sulfonylureas differedamong the quartiles, potentially affecting rates of
hypoglycemia. Sulfonylurea treatment has also been
associated with increases in body weight [27,28]. In
addition, patients in Quartile 1 had higher baseline
weight and overall obesity, whereas the baseline weight
of patients in the other 3 quartiles was more evenly
balanced. Finally, patients in Quartile 1 had the lowest
A1C at baseline compared with Quartiles 2 through 4.
It is possible that this imbalance in baseline A1C com-
bined with the greatest change in body weight and
A1C observed in Quartile 1 may have confounded the
result of higher A1C goal achievement. Exenatide ther-
apy paired with lifestyle changes may lead to improved
clinical efficacy overall. In a study of overweight or
obese patients with T2DM who failed to achieve gly-
cemic targets on metformin or sulfonylurea monother-
apy, patients randomized to exenatide twice daily plus
a program of reduced caloric intake and increased
physical activity saw significantly greater reductions in
weight (−6.2 vs −4.0 kg), A1C (−1.2% vs −0.7%), SBP
(−9.4 vs −2.0 mm Hg), and DBP (−2.2 vs +0.5 mm Hg)
compared with those randomized to lifestyle modifica-
tions and maintenance on oral therapy [29].Implications
The present analysis is consistent with the recommenda-
tions of clinical practice guidelines that weight loss, through
medical nutrition therapy and appropriately prescribed
physical activity, should be a cornerstone of therapy for
patients with T2DM [5,6]. However, most patients will
also require pharmacologic antihyperglycemic therapy.
Improvements in glycemic parameters, most CV risk
markers, and liver enzymes with exenatide once weekly
were greater in those with the greatest weight reduc-
tion. The results of the analysis also support the role of
exenatide once weekly as an effective and well-tolerated
treatment option for patients with T2DM, the majority
of whom are overweight or obese.Conclusions
Clinically important reductions in A1C and FPG were
seen with exenatide once weekly across all body weight
change quartiles, even in those patients with small reduc-
tions in body weight or small weight gain, demonstrating
that exenatide improved glycemic control independent of
weight loss. Nevertheless, the majority of patients achieved
reductions in body weight. While all body weight change
quartiles showed improvement in glycemic parameters
and the majority of quartiles showed improvement in CV
risk factors and liver enzymes, the greatest trend of im-
provement in the efficacy of exenatide once weekly was
seen in the patient quartiles with the greatest reductions
in body weight.
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